News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
717,235 Results
Type
Article (43705)
Company Profile (350)
Press Release (673180)
Section
Business (212104)
Career Advice (2175)
Deals (37064)
Drug Delivery (108)
Drug Development (84046)
Employer Resources (173)
FDA (16648)
Job Trends (15542)
News (359457)
Policy (34358)
Tag
Academia (2608)
Alliances (51905)
Alzheimer's disease (1319)
Approvals (16597)
Artificial intelligence (184)
Bankruptcy (370)
Best Places to Work (11809)
Biotechnology (221)
Breast cancer (209)
Cancer (1585)
Cardiovascular disease (134)
Career advice (1809)
CAR-T (114)
Cell therapy (326)
Clinical research (67400)
Collaboration (607)
Compensation (317)
COVID-19 (2645)
C-suite (137)
Data (1491)
Diabetes (202)
Diagnostics (6318)
Earnings (87162)
Employer resources (152)
Events (114434)
Executive appointments (506)
FDA (17440)
Funding (533)
Gene therapy (231)
GLP-1 (699)
Government (4529)
Healthcare (19070)
Infectious disease (2749)
Inflammatory bowel disease (120)
Interviews (338)
IPO (16831)
Job creations (4158)
Job search strategy (1551)
Layoffs (462)
Legal (8482)
Lung cancer (236)
Manufacturing (232)
Medical device (13370)
Medtech (13375)
Mergers & acquisitions (20490)
Metabolic disorders (552)
Neuroscience (1705)
NextGen: Class of 2025 (6720)
Non-profit (4547)
Northern California (1887)
Obesity (318)
Opinion (230)
Patents (141)
People (59141)
Phase I (20990)
Phase II (29616)
Phase III (22176)
Pipeline (625)
Postmarket research (2683)
Preclinical (8839)
Radiopharmaceuticals (248)
Rare diseases (307)
Real estate (6353)
Regulatory (22985)
Research institute (2385)
Resumes & cover letters (370)
Southern California (1628)
Startups (3784)
United States (17005)
Vaccines (612)
Weight loss (241)
Date
Today (96)
Last 7 days (431)
Last 30 days (1987)
Last 365 days (35725)
2025 (1876)
2024 (36189)
2023 (40930)
2022 (52113)
2021 (56674)
2020 (55111)
2019 (47824)
2018 (36140)
2017 (33570)
2016 (33170)
2015 (39008)
2014 (32961)
2013 (28077)
2012 (30166)
2011 (30871)
2010 (28889)
Location
Africa (804)
Arizona (212)
Asia (41251)
Australia (6546)
California (4306)
Canada (1573)
China (375)
Colorado (196)
Connecticut (209)
Europe (88232)
Florida (617)
Georgia (147)
Illinois (428)
Indiana (255)
Maryland (704)
Massachusetts (3358)
Michigan (185)
Minnesota (321)
New Jersey (1215)
New York (1214)
North Carolina (835)
Northern California (1887)
Ohio (158)
Pennsylvania (1008)
South America (1181)
Southern California (1628)
Texas (636)
Utah (124)
Washington State (437)
717,235 Results for "cocrystal pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
December 31, 2024
·
6 min read
Business
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.
May 13, 2024
·
13 min read
Press Releases
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
January 9, 2025
·
6 min read
Business
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the 12 months ended December 31, 2023, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.
March 28, 2024
·
14 min read
Drug Development
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
Cocrystal Pharma, Inc. announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human challenge clinical study evaluating the safety, tolerability, antiviral and clinical measurements of its novel, broad-spectrum, oral PB2 inhibitor CC-42344.
May 1, 2024
·
5 min read
Press Releases
Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
November 13, 2024
·
13 min read
Press Releases
Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins
October 31, 2024
·
9 min read
BioForest
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
Cocrystal Pharma, Inc. announces it has received Pre-Investigational New Drug (Pre-IND) feedback from the U.S. Food and Drug Administration (FDA) regarding CC-42344 as a potential oral treatment for pandemic and seasonal influenza A.
March 19, 2024
·
5 min read
Press Releases
CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
August 16, 2024
·
1 min read
Press Releases
Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts
September 27, 2024
·
5 min read
1 of 71,724
Next
